ketoconazole has been researched along with Prostatic Neoplasms in 181 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketoconazole has been used with success to treat disseminated intravascular coagulation and acute spinal cord compression syndromes associated with metastatic prostatic adenocarcinoma." | 8.79 | Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. ( Ahmann, FR; Dalkin, BL; Sarver, RG, 1997) |
| "To report a case of severe rhabdomyolysis resulting in acute renal failure caused by an interaction between ketoconazole and simvastatin in a patient with prostate cancer." | 7.77 | Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature. ( Atkinson, BJ; Pagliaro, LC; Watkins, JL, 2011) |
| "Ketoconazole, an antifungal drug, causes gynecomastia in some patients." | 7.67 | Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. ( Goldman, ES; Pont, A; Siiteri, PK; Stevens, DA; Sugar, AM, 1985) |
| "We report the use of ketoconazole to control disseminated intravascular coagulation due to prostatic carcinoma." | 7.67 | Emergency treatment with ketoconazole in disseminated intravascular coagulation due to metastatic prostatic carcinoma. ( Bhadoria, DP; Malhotra, KK; Mehta, S; Mittal, D; Mukhopadhyay, DK; Rao, YV, 1989) |
| "• Ketoconazole was administered by oral route at a dose of 200 mg every 8 h continuous dosing until the onset of serious adverse events or disease progression." | 6.76 | Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. ( Bajetta, E; Capone, F; Giganti, MO; Guadalupi, V; Mariani, L; Nicolai, N; Procopio, G; Salvioni, R; Valdagni, R, 2011) |
| "Biological investigations revealed a disseminated intravascular coagulation (DIC)." | 6.38 | [Favorable outcome of neoplastic disseminated intravascular coagulation treated with ketoconazole and estrogen derivative]. ( Balin, C; Fleyfel, M; Leroy, B; Marecaux, O; Plouvier, F; Scherpereel, P, 1991) |
| "Ketoconazole has been recently used in the treatment of advanced prostatic cancer and is believed to exert its effect by inhibition of androgen production." | 5.28 | Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. ( Eichenberger, T; Keating, A; Toor, P; Trachtenberg, J, 1989) |
| "A patient with spontaneous bleeding from disseminated intravascular coagulation was treated with 400 mg." | 5.27 | The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer. ( Lowe, FC; Somers, WJ, 1987) |
| "Ketoconazole has been used with success to treat disseminated intravascular coagulation and acute spinal cord compression syndromes associated with metastatic prostatic adenocarcinoma." | 4.79 | Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature. ( Ahmann, FR; Dalkin, BL; Sarver, RG, 1997) |
| "To report a case of severe rhabdomyolysis resulting in acute renal failure caused by an interaction between ketoconazole and simvastatin in a patient with prostate cancer." | 3.77 | Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature. ( Atkinson, BJ; Pagliaro, LC; Watkins, JL, 2011) |
| "In patients with prostatic cancer who had relapses after castration, few objective remissions were achieved." | 3.77 | Ketoconazole and liarozole in the treatment of advanced prostatic cancer. ( Denis, L; Mahler, C; Verhelst, J, 1993) |
| "Twenty-two patients who had progressive metastatic prostatic carcinoma (Stage D2) despite androgen-deprivation therapy (bilateral orchiectomy, 10 cases; bilateral orchiectomy followed by diethylstilbestrol, 7 cases; diethylstilbestrol, 3 cases; combined megestrol acetate and low-dose estrogen, 2 cases) were treated with ketoconazole." | 3.67 | Ketoconazole therapy for hormonally refractive metastatic prostate cancer. ( Babaian, RJ; Johnson, DE; Tenney, D; von Eschenbach, AC; Wishnow, KI, 1988) |
| "Ketoconazole, an antifungal drug, causes gynecomastia in some patients." | 3.67 | Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. ( Goldman, ES; Pont, A; Siiteri, PK; Stevens, DA; Sugar, AM, 1985) |
| "We report the use of ketoconazole to control disseminated intravascular coagulation due to prostatic carcinoma." | 3.67 | Emergency treatment with ketoconazole in disseminated intravascular coagulation due to metastatic prostatic carcinoma. ( Bhadoria, DP; Malhotra, KK; Mehta, S; Mittal, D; Mukhopadhyay, DK; Rao, YV, 1989) |
| " For 12 weeks they were treated with neoadjuvant docetaxel and ketoconazole, with dosing based on phase I data." | 2.76 | A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. ( Holzbeierlein, JM; Nisbet, AA; Reed, GA; Thrasher, JB; VanVeldhuizen, PJ; Womble, PR, 2011) |
| "• Ketoconazole was administered by oral route at a dose of 200 mg every 8 h continuous dosing until the onset of serious adverse events or disease progression." | 2.76 | Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. ( Bajetta, E; Capone, F; Giganti, MO; Guadalupi, V; Mariani, L; Nicolai, N; Procopio, G; Salvioni, R; Valdagni, R, 2011) |
| "Abiraterone acetate was well tolerated and demonstrated activity in CRPC, including in patients previously treated with ketoconazole." | 2.75 | Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. ( Fong, L; Kantoff, P; Kheoh, T; Kim, J; Lee, G; Martins, V; Molina, A; Raynaud, F; Rosenberg, JE; Ryan, CJ; Small, EJ; Smith, MR, 2010) |
| "Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy." | 2.73 | Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. ( Brown, MA; Do, KA; Logothetis, CJ; Millikan, RE; Moomey, B; Pagliaro, LC; Wen, S, 2008) |
| " Overall, the chemotherapy combined with Sr-89 was well tolerated." | 2.73 | Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. ( Amato, RJ; Henary, H; Hernandez-McClain, J, 2008) |
| "Ixabepilone is a good CYP3A4 substrate in vitro; however, in humans, it is likely to be cleared by multiple mechanisms." | 2.73 | The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. ( André, F; Cohen, M; Cömezoglu, SN; Comprelli, A; Goel, S; Goldberg, G; Horwitz, SB; Humphreys, WG; Iacono, L; Jayabalan, D; Ly, VT; Mani, S; McDaid, H; Perrin, L; Xu, C; Zhang, D, 2008) |
| "Mitoxantrone has activity similar to that of doxorubicin, is less cardiotoxic, and is widely used to treat prostate cancer." | 2.72 | Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. ( Bergan, RC; Eklund, J; Gallot, L; Jovanovic, B; Kozloff, M; Mariott, M; Pins, M; Robin, E; Schilder, L; Starr, A; Vlamakis, J, 2006) |
| " Pharmacokinetic studies were performed after docetaxel infusions on Day 1 (prior to ketoconazole) and Day 22 (after starting ketoconazole)." | 2.71 | Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. ( Aggarwal, A; Baranda, J; Reed, G; Van Veldhuizen, PJ; Williamson, S; Zulfiqar, M, 2003) |
| "The management of hormone refractory prostate cancer remains controversial." | 2.71 | An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. ( Chodak, G; Wilkinson, S, 2004) |
| "Ketoconazole (KT) has demonstrated activity in androgen independent prostate cancer (AIPC)." | 2.71 | A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. ( Arlen, P; Chen, CC; Cox, MC; Cremers, S; Dahut, WL; Figg, WD; Gulley, J; Jones, E; Liewehr, DJ; Liu, Y; Parr, A; Steinberg, SM; Yang, X; Zhai, S, 2005) |
| "Ketoconazole action dosed as 400-600 g per day was studied in 12 patients with prostatic metastasizing carcinoma." | 2.67 | [Results of a clinical trial of ketoconazole in metastatic prostatic carcinoma]. ( Morávek, P; Zita, K, 1991) |
| "A phase II clinical trial was performed to assess the antitumor activity and toxicity of ketoconazole in combination with doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH) in patients with androgen-independent prostate cancer (AI PCa)." | 2.67 | Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. ( Amato, R; Bui, C; Ellerhorst, J; Kilbourn, R; Logothetis, CJ; Sella, A; Zukiwski, AA, 1994) |
| "Ketoconazole is a nonselective steroid 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor that has been used, off-label, as a second-line therapy for castration-resistant prostate cancer (CRPC)." | 2.58 | The role of ketoconazole in current prostate cancer care. ( Liaw, B; Oh, W; Patel, V, 2018) |
| "Abiraterone has been described as a lyase selective inhibitor, yet its use still requires co-administration of prednisone to suppress such a rise of ACTH and fall in cortisol." | 2.53 | The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. ( Abbott, DH; Bird, IM, 2016) |
| "In a large proportion of advanced prostate cancer patients treated with androgen deprivation therapy, progression of the disease occurs despite low levels of testosterone, termed castration-resistant prostate cancer." | 2.45 | Novel secondary hormonal therapy in advanced prostate cancer: an update. ( Ryan, CJ; Van Allen, EM, 2009) |
| "Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death in men, following lung cancer." | 2.42 | Clinical strategies in the management of biochemical recurrence after radical prostatectomy. ( Culkin, DJ; Zimmerman, RA, 2003) |
| "For metastatic prostatic cancer presenting with an emergency oncologic condition, the treatment of choice is surgical orchiectomy, but surgery may not be possible in the presence of severe DIC." | 2.41 | Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review. ( Amornpichetkul, K; Chakrapee-Sirisuk, S; Sangruchi, T; Sinlarat, P; Srimuninnimit, V; Visudhiphan, S, 2001) |
| "The high rate of progression of prostate cancer after androgen deprivation therapy mandates that new strategies be developed." | 2.41 | Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer. ( Feldman, D; Peehl, DM; Seto, E, 2001) |
| "Prostate cancer is the most commonly diagnosed male malignancy and the second most common cause of male cancer death in the U." | 2.41 | Medical therapy of prostate cancer: 1999. ( Afrin, LB; Ergul, SM, 2000) |
| "The definition of hormone refractory prostate cancer is changing." | 2.40 | The treatment of advanced prostate cancer with ketoconazole: safety issues. ( Bok, RA; Small, EJ, 1999) |
| "The role of inhibition of aromatase in prostate cancer therapy, which was postulated for aminoglutethimide, could not be confirmed by the use of more selective aromatase inhibitors, such as formestane." | 2.39 | P450-dependent enzymes as targets for prostate cancer therapy. ( Bruynseels, J; De Coster, R; Wouters, W, 1996) |
| "Almost all patients with prostatic cancer will eventually escape the control of the first-line endocrine therapy and relapse." | 2.38 | Management of relapsing disease in prostate cancer. ( Denis, L; Mahler, C, 1992) |
| "Biological investigations revealed a disseminated intravascular coagulation (DIC)." | 2.38 | [Favorable outcome of neoplastic disseminated intravascular coagulation treated with ketoconazole and estrogen derivative]. ( Balin, C; Fleyfel, M; Leroy, B; Marecaux, O; Plouvier, F; Scherpereel, P, 1991) |
| "About one third of patients with breast cancer show objective improvement with aminoglutethimide, and it may also be of use in the treatment of adrenal carcinoma." | 2.37 | Aminoglutethimide and ketoconazole: historical perspectives and future prospects. ( Nicholls, PJ; Shaw, MA; Smith, HJ, 1988) |
| "Radiation port dermatophytosis is the occurrence of tinea corporis within the area of radiation therapy delivery." | 1.38 | Radiation port dermatophytosis: tinea corporis occurring at the site of irradiated skin. ( Casamiquela, KM; Cohen, PR, 2012) |
| " Ketoconazole increased the bioavailability of finasteride from 0." | 1.37 | In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. ( Bondesson, U; Hedeland, M; Lennernäs, H; Lundahl, A, 2011) |
| "Ketoconazole adherence was 82% (G1) and 100% (G2)." | 1.36 | Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer. ( Dowell, JE; Jean, GW; Keisner, SV; Shah, SR; Ussery, SM, 2010) |
| "Human prostate cancer PC3 cells are insensitive to calcitriol treatment." | 1.36 | CYP24A1 inhibition enhances the antitumor activity of calcitriol. ( Engler, KL; Johnson, CS; Kong, RX; Ma, Y; Muindi, JR; Trump, DL; Yu, WD, 2010) |
| "Ketoconazole has moderate activity as secondary hormonal therapy in patients with CRPC previously treated with taxane-based chemotherapy, although the TTP was short." | 1.36 | Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. ( Jacobus, S; Kantoff, PW; Nakabayashi, M; Oh, WK; Regan, MM; Rosenberg, JE; Taplin, ME, 2010) |
| "Androgens are well-known to stimulate prostate cancer (PC) growth." | 1.36 | Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer. ( Hartmann, RW; Haupenthal, J; Hille, UE; Hu, Q; Jagusch, C, 2010) |
| "Ketoconazole is a commonly used secondary hormonal therapy in castration-refractory prostate cancer (CRPC), but disease progression inevitably occurs." | 1.35 | Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. ( Balk, SP; Kantoff, PW; Nakabayashi, M; Oh, WK; Ross, RW; Sartor, O; Taplin, ME, 2009) |
| "In castration-resistant prostate cancer (CRPC) many androgen-regulated genes become re-expressed and tissue androgen levels increase despite low serum levels." | 1.35 | Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. ( Adomat, HH; Gleave, ME; Guns, ES; Hendy, SC; Locke, JA; Nelson, CC, 2009) |
| "Ketoconazole was generally well tolerated." | 1.34 | Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore. ( Ngo, LS; Tay, MH; Wong, AS; Yeo, A, 2007) |
| "We report the case of a patient with prostate cancer who develops mediastinal lymphadenopathy, pulmonary nodules and cutaneous metastases 8 years after the diagnosis." | 1.34 | [Mediastinal lymph nodes during the course of a metastatic prostate cancer]. ( Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S, 2007) |
| "The median time to disease progression or dose escalation on LDK was 3." | 1.33 | Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. ( Jackman, DM; Kantoff, PW; Nakabayashi, M; Oh, WK; Regan, MM; Xie, W, 2006) |
| "For example, androgen-independent prostate cancer cells, DU-145 and PC-3, are relatively insensitive to the anti-proliferative action of 1,25-(OH)(2)D(3)." | 1.33 | Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. ( Campbell, MJ; Simons, C; Yee, SW, 2006) |
| "LNCaP, DU145, and PC3 cells, human prostate cancer cell lines, and HL60, a human leukemia cell line, were lysed and soluble proteins were harvested." | 1.31 | Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines. ( Blagosklonny, MV; Dixon, SC; Figg, WD, 2000) |
| "In patients with metastatic prostate cancer, we are evaluating the addition of the bisphosphonate alendronate when added to ketoconazole for impact on matrix metalloproteinase (MMP)-2 and MMP-9 as well as traditional clinical endpoints." | 1.31 | National Cancer Institute intramural approach to advanced prostate cancer. ( Arlen, PM; Cox, MC; Dahut, W; Figg, WD; Gulley, J; Linehan, WM, 2002) |
| "Clonal assays with primary cultures of human prostatic cancer cells were performed to test anti-proliferative effects of ketoconazole alone or in combination with calcitriol or EB 1089." | 1.31 | Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. ( Feldman, D; Hsu, JY; Peehl, DM; Seto, E, 2002) |
| "at bedtime)." | 1.31 | Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. ( Bok, RA; Harris, KA; Kakefuda, M; Small, EJ; Weinberg, V, 2002) |
| "Two patients with progressive prostate cancer were removed from this study and subsequently placed on ketoconazole, as a palliative agent." | 1.30 | In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3. ( Dixon, SC; Figg, WD; Giordano, C; Lush, RM; Reed, E; Venzon, D; Zalles, A, 1997) |
| "Sections of benign prostatic hyperplasia and prostatic carcinoma from each patient were stained with antibodies to AR and GR using an avidin-biotin peroxidase technique." | 1.29 | Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. ( Chen, Y; Cidlowski, JA; French, FS; Hall, SH; Hamil, K; Mohler, JL; Sar, M; Wilson, EM, 1996) |
| "Metastases to the meninges from prostatic cancer are rare, accounting for less than 0." | 1.29 | Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. ( DeAngelis, LM; Mencel, PJ; Motzer, RJ, 1994) |
| "Ketoconazole was generally well tolerated." | 1.28 | High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. ( Cummings, KB; Havlin, KH; Jordan, VC; Lange, PH; Messing, EM; Trump, DL, 1989) |
| "Ketoconazole is an antifungal azole derivative which also inhibits the cytochrome P-450(17)alpha, catalyzing the conversion of progestins into androgens." | 1.28 | Comparative effects of ketoconazole on rat, dog and human testicular steroidogenesis. ( Beerens, D; Coene, MC; Cools, W; De Coster, R; Van Camp, C; Van Camp, K, 1989) |
| "Ketoconazole has been recently used in the treatment of advanced prostatic cancer and is believed to exert its effect by inhibition of androgen production." | 1.28 | Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. ( Eichenberger, T; Keating, A; Toor, P; Trachtenberg, J, 1989) |
| "Ketoconazole has been recently used in the primary treatment of patients with metastatic cancer of the prostate and is identified as a potent inhibitor of cytochrome P450-dependent adrenal and testicular androgen production." | 1.28 | Synergistic effect of ketoconazole and antineoplastic agents on hormone-independent prostatic cancer cells. ( Chronis, P; Eichenberger, T; Keating, A; Trachtenberg, J, 1989) |
| "Fifteen patients with biopsy-proven prostate cancer were treated with ketoconazole 400 mg every 8 h." | 1.27 | Ketoconazole therapy for advanced prostate cancer. ( Pont, A; Trachtenberg, J, 1984) |
| "Ketoconazole is a potent inhibitor of the P450 series of enzymes that are essential for the production of androgens." | 1.27 | The effects of ketoconazole on testosterone production and normal and malignant androgen dependent tissues of the adult rat. ( Trachtenberg, J, 1984) |
| "Ketoconazole can suppress androgen production and has a beneficial role in the hormonal therapy of patients with prostate cancer who have not undergone orchiectomy." | 1.27 | High-dose ketoconazole therapy in patients with metastatic prostate cancer. ( Al-Sarraf, M; Decker, DA; Kresge, C; Subramanian, MG; Tapazoglou, E, 1986) |
| "Ketoconazole is an antifungal agent that, in high doses, inhibits testicular and adrenal steroid synthesis." | 1.27 | Steroid synthesis inhibition by ketoconazole: sites of action. ( Trachtenberg, J; Zadra, J, 1988) |
| "Eleven previously untreated patients with stage D prostate cancer were treated with ketoconazole in a dosage of 400 mg p." | 1.27 | High-dose ketoconazole to untreated stage D prostate cancer. ( Aabo, K; Hansen, HH; Kjaer, M, 1988) |
| "Ketoconazole has now been withdrawn as a treatment for prostatic cancer." | 1.27 | Ketoconazole as primary treatment of prostatic cancer. ( Beastall, G; Kirk, D; Moffat, LE; Smith, MF; Tolley, DA, 1988) |
| "A patient with spontaneous bleeding from disseminated intravascular coagulation was treated with 400 mg." | 1.27 | The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer. ( Lowe, FC; Somers, WJ, 1987) |
| " Ketoconazole, a systemic antifungal drug, was evaluated in a dosage of 200 mg 8-hourly given orally as an alternative method of lowering serum testosterone levels." | 1.27 | High-dose ketoconazole therapy in prostatic cancer. A pilot study. ( Nicolle, P; Pontin, A; Sarembock, L, 1985) |
| "We report a case of prostatic cancer in which ketoconazole resulted in rapid and sustained reduction in serum androgens as well as rapid induction of a clinical remission." | 1.27 | Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. ( Halpern, N; Pont, A; Trachtenberg, J, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 65 (35.91) | 18.7374 |
| 1990's | 34 (18.78) | 18.2507 |
| 2000's | 49 (27.07) | 29.6817 |
| 2010's | 32 (17.68) | 24.3611 |
| 2020's | 1 (0.55) | 2.80 |
| Authors | Studies |
|---|---|
| Rowlands, MG | 3 |
| Barrie, SE | 3 |
| Chan, F | 1 |
| Houghton, J | 2 |
| Jarman, M | 3 |
| McCague, R | 1 |
| Potter, GA | 3 |
| Chan, FC | 1 |
| Haynes, BP | 1 |
| Njar, VC | 4 |
| Kato, K | 2 |
| Nnane, IP | 3 |
| Grigoryev, DN | 2 |
| Long, BJ | 2 |
| Brodie, AM | 5 |
| Patel, JB | 1 |
| Huynh, CK | 1 |
| Handratta, VD | 2 |
| Gediya, LK | 2 |
| Goloubeva, OG | 1 |
| Clement, OO | 1 |
| Nanne, IP | 1 |
| Soprano, DR | 1 |
| Vasaitis, TS | 1 |
| Kataria, R | 1 |
| Chopra, P | 1 |
| Newman, D | 1 |
| Farquhar, R | 1 |
| Guo, Z | 1 |
| Qiu, Y | 1 |
| Pinto-Bazurco Mendieta, MA | 1 |
| Negri, M | 1 |
| Jagusch, C | 3 |
| Müller-Vieira, U | 1 |
| Lauterbach, T | 1 |
| Hartmann, RW | 5 |
| Hu, Q | 2 |
| Yin, L | 1 |
| Hille, UE | 2 |
| Haupenthal, J | 1 |
| Lundahl, A | 1 |
| Hedeland, M | 1 |
| Bondesson, U | 1 |
| Lennernäs, H | 1 |
| Bratoeff, E | 1 |
| Garrido, M | 1 |
| Ramírez-Apan, T | 1 |
| Heuze, Y | 1 |
| Sánchez, A | 1 |
| Soriano, J | 1 |
| Cabeza, M | 1 |
| Guengerich, FP | 1 |
| McCarty, KD | 1 |
| Chapman, JG | 1 |
| Tateishi, Y | 1 |
| Patel, V | 1 |
| Liaw, B | 1 |
| Oh, W | 1 |
| Amato, RJ | 3 |
| Saxena, S | 1 |
| Stepankiw, M | 1 |
| Aggarwal, R | 1 |
| Halabi, S | 3 |
| Kelly, WK | 1 |
| George, D | 1 |
| Mahoney, JF | 1 |
| Millard, F | 1 |
| Stadler, WM | 2 |
| Morris, MJ | 1 |
| Kantoff, P | 4 |
| Monk, JP | 1 |
| Carducci, M | 1 |
| Small, EJ | 9 |
| Robles-Escajeda, E | 1 |
| Martínez, A | 1 |
| Varela-Ramirez, A | 1 |
| Sánchez-Delgado, RA | 1 |
| Aguilera, RJ | 1 |
| Mostaghel, EA | 1 |
| Nelson, PS | 1 |
| Lange, P | 1 |
| Lin, DW | 1 |
| Taplin, ME | 4 |
| Balk, S | 1 |
| Ellis, W | 1 |
| Marck, B | 1 |
| Tamae, D | 1 |
| Matsumoto, AM | 1 |
| True, LD | 1 |
| Vessella, R | 1 |
| Penning, T | 1 |
| Hunter Merrill, R | 1 |
| Gulati, R | 1 |
| Montgomery, B | 1 |
| Peer, A | 2 |
| Gottfried, M | 2 |
| Sinibaldi, V | 2 |
| Carducci, MA | 4 |
| Eisenberger, MA | 3 |
| Sella, A | 4 |
| Leibowitz-Amit, R | 1 |
| Berger, R | 1 |
| Keizman, D | 3 |
| Trump, D | 1 |
| Pokuri, VK | 1 |
| Nourkeyhani, H | 1 |
| Betsy, B | 1 |
| Herbst, L | 1 |
| Sikorski, M | 1 |
| Spangenthal, E | 1 |
| Fabiano, A | 1 |
| George, S | 1 |
| Bird, IM | 1 |
| Abbott, DH | 1 |
| Millikan, RE | 3 |
| Wen, S | 2 |
| Pagliaro, LC | 4 |
| Brown, MA | 2 |
| Moomey, B | 1 |
| Do, KA | 1 |
| Logothetis, CJ | 5 |
| Hernandez-McClain, J | 1 |
| Henary, H | 1 |
| Van Allen, EM | 1 |
| Ryan, CJ | 6 |
| Galsky, MD | 1 |
| Simon, K | 1 |
| Sonpavde, G | 1 |
| Hutson, TE | 1 |
| Fleming, M | 1 |
| Kondagunta, GV | 1 |
| Berry, W | 1 |
| Locke, JA | 1 |
| Nelson, CC | 1 |
| Adomat, HH | 1 |
| Hendy, SC | 1 |
| Gleave, ME | 1 |
| Guns, ES | 1 |
| Sartor, O | 2 |
| Nakabayashi, M | 3 |
| Ross, RW | 1 |
| Kantoff, PW | 5 |
| Balk, SP | 2 |
| Oh, WK | 5 |
| Jacobus, S | 1 |
| Regan, MM | 3 |
| Rosenberg, JE | 2 |
| Ko, YJ | 1 |
| Bubley, GJ | 1 |
| Duggan, SE | 1 |
| Werner, L | 1 |
| Beer, TM | 1 |
| Ryan, CW | 1 |
| Mathew, P | 1 |
| Tu, SM | 2 |
| Denmeade, SR | 1 |
| Mantzoros, CS | 1 |
| Rittmaster, R | 1 |
| Smith, MR | 2 |
| Fong, L | 2 |
| Raynaud, F | 1 |
| Martins, V | 1 |
| Lee, G | 1 |
| Kheoh, T | 1 |
| Kim, J | 2 |
| Molina, A | 1 |
| Figg, WD | 5 |
| Woo, S | 1 |
| Zhu, W | 1 |
| Chen, X | 1 |
| Ajiboye, AS | 1 |
| Steinberg, SM | 2 |
| Price, DK | 1 |
| Wright, JJ | 1 |
| Parnes, HL | 1 |
| Arlen, PM | 2 |
| Gulley, JL | 1 |
| Dahut, WL | 2 |
| Muindi, JR | 2 |
| Yu, WD | 1 |
| Ma, Y | 1 |
| Engler, KL | 1 |
| Kong, RX | 1 |
| Trump, DL | 2 |
| Johnson, CS | 1 |
| Keisner, SV | 1 |
| Shah, SR | 1 |
| Jean, GW | 1 |
| Ussery, SM | 1 |
| Dowell, JE | 1 |
| Procopio, G | 1 |
| Guadalupi, V | 1 |
| Giganti, MO | 1 |
| Mariani, L | 1 |
| Salvioni, R | 1 |
| Nicolai, N | 1 |
| Capone, F | 1 |
| Valdagni, R | 1 |
| Bajetta, E | 1 |
| Watkins, JL | 1 |
| Atkinson, BJ | 1 |
| Agarwal, N | 2 |
| Vogelzang, NJ | 3 |
| Miller, K | 1 |
| Huang, P | 1 |
| Womble, PR | 1 |
| VanVeldhuizen, PJ | 1 |
| Nisbet, AA | 1 |
| Reed, GA | 1 |
| Thrasher, JB | 1 |
| Holzbeierlein, JM | 1 |
| Lin, GW | 3 |
| Yao, XD | 3 |
| Ye, DW | 3 |
| Casamiquela, KM | 1 |
| Cohen, PR | 2 |
| Zhang, SL | 2 |
| Dai, B | 2 |
| Zhang, HL | 2 |
| Shen, YJ | 2 |
| Zhu, Y | 2 |
| Zhu, YP | 1 |
| Shi, GH | 1 |
| Ma, CG | 2 |
| Xiao, WJ | 1 |
| Qin, XJ | 1 |
| Kim, W | 1 |
| Ish-Shalom, M | 1 |
| Maimon, N | 1 |
| Neumann, A | 1 |
| Rosenbaum, E | 1 |
| Kovel, S | 1 |
| Pili, R | 1 |
| Hammers, H | 1 |
| Harris, KA | 1 |
| Weinberg, V | 2 |
| Bok, RA | 2 |
| Kakefuda, M | 1 |
| Peehl, DM | 2 |
| Seto, E | 2 |
| Hsu, JY | 1 |
| Feldman, D | 2 |
| Itakura, H | 1 |
| Vaughn, D | 1 |
| Haller, DG | 1 |
| O'Dwyer, PJ | 1 |
| Millikan, R | 1 |
| Thall, PF | 2 |
| Lee, SJ | 1 |
| Jones, D | 1 |
| Cannon, MW | 1 |
| Kuebler, JP | 1 |
| Wade, J | 1 |
| Van Veldhuizen, PJ | 1 |
| Reed, G | 1 |
| Aggarwal, A | 1 |
| Baranda, J | 1 |
| Zulfiqar, M | 1 |
| Williamson, S | 1 |
| Walczak, JR | 1 |
| Dawson, NA | 1 |
| Rini, BI | 1 |
| Picus, J | 1 |
| Gable, P | 1 |
| Torti, FM | 2 |
| Kaplan, E | 1 |
| Zimmerman, RA | 1 |
| Culkin, DJ | 1 |
| Gulley, J | 2 |
| Cox, MC | 2 |
| Linehan, WM | 1 |
| Dahut, W | 1 |
| Wilkinson, S | 1 |
| Chodak, G | 1 |
| Hagmann, E | 1 |
| Manola, J | 1 |
| George, DJ | 1 |
| Gilligan, TD | 1 |
| Jacobson, JO | 1 |
| Kaufman, DS | 1 |
| Liu, Y | 3 |
| Arlen, P | 1 |
| Liewehr, DJ | 1 |
| Zhai, S | 1 |
| Cremers, S | 1 |
| Parr, A | 1 |
| Yang, X | 1 |
| Chen, CC | 1 |
| Jones, E | 1 |
| Conte, C | 1 |
| Floridi, A | 2 |
| Aisa, C | 1 |
| Piroddi, M | 1 |
| Galli, F | 1 |
| Scholz, M | 1 |
| Jennrich, R | 1 |
| Strum, S | 1 |
| Brosman, S | 1 |
| Johnson, H | 1 |
| Lam, R | 1 |
| Hobdy, EM | 1 |
| Shafi, NQ | 1 |
| Kummar, S | 1 |
| Yee, SW | 1 |
| Campbell, MJ | 1 |
| Simons, C | 1 |
| Eklund, J | 1 |
| Kozloff, M | 1 |
| Vlamakis, J | 1 |
| Starr, A | 1 |
| Mariott, M | 1 |
| Gallot, L | 1 |
| Jovanovic, B | 1 |
| Schilder, L | 1 |
| Robin, E | 1 |
| Pins, M | 1 |
| Bergan, RC | 1 |
| Argirovic, Dj | 1 |
| Liebertz, C | 1 |
| Fox, P | 1 |
| Xie, W | 1 |
| Jackman, DM | 1 |
| Drăgan, CA | 1 |
| Bureik, M | 1 |
| Stein, CA | 1 |
| Goel, S | 2 |
| Ghavamian, R | 1 |
| Ou, SS | 1 |
| Agarwal, MM | 1 |
| Singh, SK | 1 |
| Acharya, NC | 1 |
| Mete, UK | 1 |
| Mandal, AK | 1 |
| Roca Edreira, A | 1 |
| Aguilera Tubet, C | 1 |
| Villanueva Peña, A | 1 |
| Ballestero Diego, R | 1 |
| Zubillaga Guerrero, S | 1 |
| Rosenberg, J | 1 |
| Lin, A | 1 |
| Logothetis, C | 1 |
| Williams, D | 1 |
| Ngo, LS | 1 |
| Yeo, A | 1 |
| Wong, AS | 1 |
| Tay, MH | 1 |
| Lainakis, G | 1 |
| Nikos, A | 1 |
| Gerassimos, A | 1 |
| Michael, C | 1 |
| Iraklis, M | 1 |
| Konstantinos, L | 1 |
| Ioannis, V | 1 |
| Harilaos, K | 1 |
| Dimopoulos, MA | 1 |
| Bamias, A | 1 |
| Cohen, M | 1 |
| Cömezoglu, SN | 1 |
| Perrin, L | 1 |
| André, F | 1 |
| Jayabalan, D | 1 |
| Iacono, L | 1 |
| Comprelli, A | 1 |
| Ly, VT | 1 |
| Zhang, D | 1 |
| Xu, C | 1 |
| Humphreys, WG | 1 |
| McDaid, H | 1 |
| Goldberg, G | 1 |
| Horwitz, SB | 1 |
| Mani, S | 1 |
| Williams, G | 4 |
| Bloom, SR | 3 |
| Trachtenberg, J | 11 |
| Mahler, C | 7 |
| Chaban, M | 2 |
| Robinson, M | 1 |
| Denis, L | 7 |
| Pont, A | 5 |
| Halpern, N | 1 |
| Allen, JM | 1 |
| Kerle, DJ | 2 |
| Ware, H | 2 |
| Doble, A | 2 |
| Kilbourn, R | 1 |
| Amato, R | 1 |
| Bui, C | 1 |
| Zukiwski, AA | 1 |
| Ellerhorst, J | 1 |
| Polsen, JA | 1 |
| Sergejew, T | 1 |
| Siegsmund, MJ | 1 |
| Cardarelli, C | 1 |
| Aksentijevich, I | 1 |
| Sugimoto, Y | 1 |
| Pastan, I | 1 |
| Gottesman, MM | 1 |
| Young, CW | 1 |
| Warrell, RP | 1 |
| Mencel, PJ | 1 |
| DeAngelis, LM | 1 |
| Motzer, RJ | 1 |
| Verhelst, J | 1 |
| De Coster, R | 7 |
| Wouters, W | 1 |
| Bruynseels, J | 1 |
| Dixon, SC | 2 |
| Zalles, A | 1 |
| Giordano, C | 1 |
| Lush, RM | 1 |
| Venzon, D | 1 |
| Reed, E | 1 |
| Baron, AD | 1 |
| Fippin, L | 1 |
| Apodaca, D | 1 |
| Sarver, RG | 1 |
| Dalkin, BL | 1 |
| Ahmann, FR | 1 |
| Petrylak, DP | 1 |
| Abi-Rashid, B | 1 |
| Baron, A | 1 |
| Bok, R | 1 |
| Bare, RL | 1 |
| Lu, Q | 1 |
| Wang, X | 1 |
| Ling, YZ | 2 |
| Brodie, A | 1 |
| Ellerhorst, JA | 1 |
| Finn, L | 2 |
| Jackson, A | 1 |
| Mohler, JL | 1 |
| Chen, Y | 1 |
| Hamil, K | 1 |
| Hall, SH | 1 |
| Cidlowski, JA | 1 |
| Wilson, EM | 1 |
| French, FS | 1 |
| Sar, M | 1 |
| Blagosklonny, MV | 1 |
| Pettaway, CA | 1 |
| Pisters, LL | 1 |
| Troncoso, P | 1 |
| Slaton, J | 1 |
| Kamoi, K | 1 |
| Afrin, LB | 1 |
| Ergul, SM | 1 |
| Takeda, M | 1 |
| Hosaka, M | 1 |
| Rickman, T | 1 |
| Garmany, R | 1 |
| Doherty, T | 1 |
| Benson, D | 1 |
| Okusa, MD | 1 |
| Chakrapee-Sirisuk, S | 1 |
| Amornpichetkul, K | 1 |
| Visudhiphan, S | 1 |
| Sangruchi, T | 1 |
| Srimuninnimit, V | 1 |
| Sinlarat, P | 1 |
| Percy, LA | 1 |
| Huben, RP | 1 |
| Gerber, GS | 1 |
| Chodak, GW | 1 |
| Blackard, CE | 1 |
| Masubuchi, Y | 1 |
| Watanabe, M | 1 |
| Kumai, T | 1 |
| Tanaka, M | 1 |
| Akaike, M | 1 |
| Hirai, M | 1 |
| Morávek, P | 1 |
| Zita, K | 1 |
| McConnell, JD | 1 |
| Fleyfel, M | 1 |
| Leroy, B | 1 |
| Plouvier, F | 1 |
| Balin, C | 1 |
| Marecaux, O | 1 |
| Scherpereel, P | 1 |
| Ahmad, S | 1 |
| Lowe, FC | 3 |
| Bamberger, MH | 2 |
| Debruyne, FM | 3 |
| Havlin, KH | 1 |
| Messing, EM | 1 |
| Cummings, KB | 1 |
| Lange, PH | 1 |
| Jordan, VC | 1 |
| Eichenberger, T | 4 |
| Chronis, P | 1 |
| Keating, A | 2 |
| Bhadoria, DP | 1 |
| Mukhopadhyay, DK | 1 |
| Mehta, S | 1 |
| Mittal, D | 1 |
| Rao, YV | 1 |
| Malhotra, KK | 1 |
| Witjes, FJ | 1 |
| Fernandez del Moral, P | 1 |
| Geboers, AD | 1 |
| Jubelirer, SJ | 1 |
| Hogan, T | 1 |
| Van Wauwe, JP | 1 |
| Janssen, PA | 1 |
| Coene, MC | 3 |
| Van Camp, C | 1 |
| Van Camp, K | 1 |
| Beerens, D | 3 |
| Cools, W | 1 |
| Hanash, KA | 1 |
| Lamberts, SW | 1 |
| Uitterlinden, P | 1 |
| de Jong, FH | 1 |
| White, MC | 1 |
| Kendall-Taylor, P | 1 |
| Aabo, K | 2 |
| Toor, P | 1 |
| Tapazoglou, E | 1 |
| Subramanian, MG | 1 |
| Al-Sarraf, M | 1 |
| Kresge, C | 1 |
| Decker, DA | 1 |
| Caers, I | 2 |
| Amery, W | 2 |
| Haelterman, C | 2 |
| Vanuytsel, L | 1 |
| Ang, KK | 1 |
| Vantongelen, K | 1 |
| Drochmans, A | 2 |
| Baert, L | 1 |
| van der Schueren, E | 2 |
| Sogani, PC | 1 |
| Fair, WR | 1 |
| Zadra, J | 1 |
| Shaw, MA | 1 |
| Nicholls, PJ | 1 |
| Smith, HJ | 1 |
| Waxman, J | 1 |
| Oelschläger, H | 1 |
| Rothley, D | 1 |
| Dunzendorfer, U | 1 |
| Scultéty, S | 1 |
| Oszlánczy, J | 1 |
| Faredin, I | 1 |
| Tóth, I | 1 |
| Sonino, N | 2 |
| Johnson, DE | 1 |
| Babaian, RJ | 1 |
| von Eschenbach, AC | 1 |
| Wishnow, KI | 1 |
| Tenney, D | 1 |
| Miettinen, TA | 1 |
| Flamm, J | 1 |
| Sagaster, P | 1 |
| Teich, G | 1 |
| Köhn, H | 1 |
| Miksche, M | 1 |
| Kjaer, M | 1 |
| Hansen, HH | 1 |
| Moffat, LE | 1 |
| Kirk, D | 1 |
| Tolley, DA | 1 |
| Smith, MF | 1 |
| Beastall, G | 1 |
| Hassellund, S | 2 |
| Norman, N | 1 |
| Sander, S | 2 |
| Somers, WJ | 1 |
| Litt, MR | 1 |
| Bell, WR | 1 |
| Lepor, HA | 1 |
| Normann, N | 1 |
| Witjes, FA | 1 |
| Kraemer, FB | 1 |
| Rajfer, J | 1 |
| Sikka, SC | 1 |
| Rivera, F | 1 |
| Handelsman, DJ | 1 |
| Namer, M | 1 |
| Boublil, JL | 1 |
| Kather, R | 1 |
| Cavaglione, G | 1 |
| Svábenský, M | 1 |
| Castillo Cádiz, O | 1 |
| Martínez Sanz, P | 1 |
| Hopkins, S | 1 |
| Smith, JB | 1 |
| Ghayad, PY | 1 |
| Dhabuwala, CB | 1 |
| Drelichman, A | 1 |
| Pierce, JM | 1 |
| Dubost, JJ | 1 |
| Sauvezie, B | 1 |
| Ristori, JM | 1 |
| Thevenet, JP | 1 |
| Rampon, S | 1 |
| Heyns, W | 1 |
| Verhoeven, G | 1 |
| Dunlop, H | 1 |
| Smith, C | 1 |
| Allen, J | 1 |
| Yeo, T | 1 |
| Nicolle, P | 1 |
| Pontin, A | 1 |
| Sarembock, L | 1 |
| Goldman, ES | 1 |
| Sugar, AM | 1 |
| Siiteri, PK | 1 |
| Stevens, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer[NCT00298155] | Phase 2 | 35 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate[NCT00002855] | Phase 3 | 306 participants (Actual) | Interventional | 1996-08-31 | Completed | ||
| A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| Phase II Randomized Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels[NCT02867020] | Phase 2 | 128 participants (Actual) | Interventional | 2017-10-11 | Completed | ||
| Mechanisms of Control of the Intratesticular Hormonal Milieu in Man[NCT01215292] | Phase 1/Phase 2 | 46 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone[NCT03261336] | Phase 2 | 1 participants (Actual) | Interventional | 2017-01-06 | Terminated (stopped due to can not meet enrollment) | ||
| A Randomized Phase II Trial of Taxol/VP-16/Estramustine vs. Ketoconazole/Doxorubicin/Vinblastine/Estramustine in Androgen Independent Prostate Cancer[NCT00003084] | Phase 2 | 75 participants (Actual) | Interventional | 1997-12-31 | Completed | ||
| A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Paclitaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients With a Rising PSA After Hormonal Therapy f[NCT00027859] | Phase 3 | 0 participants | Interventional | 2003-10-08 | Completed | ||
| A PHASE III TWO-ARM RANDOMIZED STUDY COMPARING ANTIANDROGEN WITHDRAWAL ALONE VERSUS ANTIANDROGEN WITHDRAWAL COMBINED WITH KETOCONAZOLE AND HYDROCORTISON IN PATIENTS WITH ADVANCED PROSTAGE CANCER[NCT00002760] | Phase 3 | 260 participants (Actual) | Interventional | 1996-08-31 | Completed | ||
| A Phase I Study of Estramustine, Taxotere and Carboplatin (ETP) in Patients With Horomone Refractory Prostate Cancer[NCT00005627] | Phase 1 | 0 participants | Interventional | 1999-03-31 | Completed | ||
| SMART Optimization of a Parenting Program for Active-duty Families[NCT05509348] | 423 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone In Patients With Advanced Cancer[NCT00096317] | Phase 1 | 29 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Mechanisms of Hormonal Control of Spermatogenesis in Man[NCT02147964] | Phase 2 | 0 participants (Actual) | Interventional | 2019-06-30 | Withdrawn (stopped due to No funding was obtained for this study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Tissue dihydrotesterone (DHT) (NCT00298155)
Timeframe: After 12 weeks of neoadjuvant androgen deprivation
| Intervention | ng/g (Mean) |
|---|---|
| Group 1 | 0.03 |
| Group 2 | 0.06 |
| Group 3 | 0.03 |
Serum DHT (NCT00298155)
Timeframe: After 12 weeks of neoadjuvant androgen deprivation
| Intervention | ng/dL (Mean) |
|---|---|
| Group 1 | 4.2 |
| Group 2 | 3.6 |
| Group 3 | 5.7 |
Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 3 |
Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 2 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel (Tgel)+ Placebo | .87 |
| Acyline + Tgel + Ketoconazole 400mg | 0.5 |
| Acyline + Tgel + Ketoconazole 800mg | 0.12 |
| Acyline & TGel & Dutasteride 2.5mg | 1.7 |
| Acyline & TGel & Anastrazole 1mg | 3.6 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel (Tgel)+ Placebo | 3.17 |
| Acyline & TGel & Ketoconazole 400 mg | 2.08 |
| Acyline & TGel & Ketoconazole 800 mg | 1.46 |
| Acyline & TGel & Dutasteride | 0.12 |
| Acyline & TGel & Anastrazole | 3.63 |
(NCT01215292)
Timeframe: 10 days
| Intervention | ng/mL (Median) |
|---|---|
| Acyline + Testosterone Gel + Placebo | 14 |
| Acyline + Tgel + Ketoconazole 400mg | 3.7 |
| Acyline + Tgel + Ketoconazole 800mg | 1.7 |
| Acyline & TGel & Dutasteride 2.5mg | 18.4 |
| Acyline & TGel & Anastrazole 1mg | 24.0 |
Descriptive analysis of observed toxicity and patient reports of tolerating experimental treatment (NCT03261336)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Calcitriol, Ketoconazole, Hydrocortisone | 1 |
31 reviews available for ketoconazole and Prostatic Neoplasms
| Article | Year |
|---|---|
The role of ketoconazole in current prostate cancer care.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; Humans; Ketoconazole; Male; Prostatic Neop | 2018 |
The role of ketoconazole in current prostate cancer care.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; Humans; Ketoconazole; Male; Prostatic Neop | 2018 |
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Topics: Adrenal Hyperplasia, Congenital; Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; | 2016 |
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Topics: Adrenal Hyperplasia, Congenital; Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; | 2016 |
Novel secondary hormonal therapy in advanced prostate cancer: an update.
Topics: Androgen Antagonists; Androstenes; Androstenols; Disease Progression; Humans; Ketoconazole; Male; Pr | 2009 |
Novel secondary hormonal therapy in advanced prostate cancer: an update.
Topics: Androgen Antagonists; Androstenes; Androstenols; Disease Progression; Humans; Ketoconazole; Male; Pr | 2009 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormo | 2011 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormo | 2011 |
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agen | 2012 |
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agen | 2012 |
Clinical strategies in the management of biochemical recurrence after radical prostatectomy.
Topics: Androgen Antagonists; Antifungal Agents; Cytochrome P-450 Enzyme System; Disease-Free Survival; Flut | 2003 |
Clinical strategies in the management of biochemical recurrence after radical prostatectomy.
Topics: Androgen Antagonists; Antifungal Agents; Cytochrome P-450 Enzyme System; Disease-Free Survival; Flut | 2003 |
Ketoconazole as a secondary hormonal intervention in advanced prostate cancer.
Topics: Adrenergic Antagonists; Antineoplastic Agents, Hormonal; Humans; Ketoconazole; Male; Prostatic Neopl | 2006 |
Ketoconazole as a secondary hormonal intervention in advanced prostate cancer.
Topics: Adrenergic Antagonists; Antineoplastic Agents, Hormonal; Humans; Ketoconazole; Male; Prostatic Neopl | 2006 |
Secondary hormonal manipulations in prostate cancer.
Topics: Androgen Antagonists; Estrogens; Humans; Ketoconazole; Male; Prostatic Neoplasms; Receptors, Androge | 2006 |
Secondary hormonal manipulations in prostate cancer.
Topics: Androgen Antagonists; Estrogens; Humans; Ketoconazole; Male; Prostatic Neoplasms; Receptors, Androge | 2006 |
Clinical pharmacology of all-trans retinoic acid.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Ketoconazole; Leukemia, Promyelocytic, Acute; Lung Neoplasms | 1994 |
Clinical pharmacology of all-trans retinoic acid.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Ketoconazole; Leukemia, Promyelocytic, Acute; Lung Neoplasms | 1994 |
Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Glucocorticoids; Humans; Imidazoles; Ketoconazole; Ma | 1993 |
Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Glucocorticoids; Humans; Imidazoles; Ketoconazole; Ma | 1993 |
P450-dependent enzymes as targets for prostate cancer therapy.
Topics: Adenocarcinoma; Aldehyde-Lyases; Androgen Antagonists; Androgens; Animals; Antineoplastic Agents, Ho | 1996 |
P450-dependent enzymes as targets for prostate cancer therapy.
Topics: Adenocarcinoma; Aldehyde-Lyases; Androgen Antagonists; Androgens; Animals; Antineoplastic Agents, Ho | 1996 |
Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature.
Topics: Adenocarcinoma; Adrenal Gland Diseases; Aged; Bone Neoplasms; Humans; Ketoconazole; Male; Prostatic | 1997 |
Ketoconazole-induced adrenal crisis in a patient with metastatic prostatic adenocarcinoma: case report and review of the literature.
Topics: Adenocarcinoma; Adrenal Gland Diseases; Aged; Bone Neoplasms; Humans; Ketoconazole; Male; Prostatic | 1997 |
Therapy for hormone-resistant prostate cancer: no longer a myth.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Ne | 1996 |
Therapy for hormone-resistant prostate cancer: no longer a myth.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Ne | 1996 |
Endocrine therapy of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Antineoplasti | 1998 |
Endocrine therapy of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Antineoplasti | 1998 |
The treatment of advanced prostate cancer with ketoconazole: safety issues.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Humans; Ketoconazole; Male; Prostatic Neoplasms | 1999 |
The treatment of advanced prostate cancer with ketoconazole: safety issues.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Humans; Ketoconazole; Male; Prostatic Neoplasms | 1999 |
Treating prostate cancer. Part V: androgen deprivation and chemotherapy.
Topics: Androgen Antagonists; Estrogens; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Orchiec | 1999 |
Treating prostate cancer. Part V: androgen deprivation and chemotherapy.
Topics: Androgen Antagonists; Estrogens; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Orchiec | 1999 |
Medical therapy of prostate cancer: 1999.
Topics: Androgen Antagonists; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combi | 2000 |
Medical therapy of prostate cancer: 1999.
Topics: Androgen Antagonists; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combi | 2000 |
[Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Topics: 17-Hydroxysteroid Dehydrogenases; Androgen Antagonists; Androstenes; Androstenols; Animals; Antineop | 2000 |
[Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Topics: 17-Hydroxysteroid Dehydrogenases; Androgen Antagonists; Androstenes; Androstenols; Animals; Antineop | 2000 |
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Drug Synergism; Hu | 2001 |
Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Drug Synergism; Hu | 2001 |
Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review.
Topics: Antifungal Agents; Antineoplastic Agents, Hormonal; Disseminated Intravascular Coagulation; Drug The | 2001 |
Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review.
Topics: Antifungal Agents; Antineoplastic Agents, Hormonal; Disseminated Intravascular Coagulation; Drug The | 2001 |
Management of relapsing disease in prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Estrogens | 1992 |
Management of relapsing disease in prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Estrogens | 1992 |
Ketoconazole in advanced prostate cancer.
Topics: Carcinoma; Hormones; Humans; Ketoconazole; Male; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms; | 1992 |
Ketoconazole in advanced prostate cancer.
Topics: Carcinoma; Hormones; Humans; Ketoconazole; Male; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms; | 1992 |
Physiologic basis of endocrine therapy for prostatic cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Androgens; Estrogens; Gonadotropin-Releasing Hormone; Human | 1991 |
Physiologic basis of endocrine therapy for prostatic cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Androgens; Estrogens; Gonadotropin-Releasing Hormone; Human | 1991 |
[Favorable outcome of neoplastic disseminated intravascular coagulation treated with ketoconazole and estrogen derivative].
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy, Needle; Blood Coagulation Tests; Diethylstilbestrol; | 1991 |
[Favorable outcome of neoplastic disseminated intravascular coagulation treated with ketoconazole and estrogen derivative].
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy, Needle; Blood Coagulation Tests; Diethylstilbestrol; | 1991 |
High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and review of the literature.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Diethylstilbestrol; Humans; Ketoconazole; Male; Middle Aged | 1989 |
High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and review of the literature.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Diethylstilbestrol; Humans; Ketoconazole; Male; Middle Aged | 1989 |
Is there a case for P-450 inhibitors in cancer treatment?
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzym | 1989 |
Is there a case for P-450 inhibitors in cancer treatment?
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzym | 1989 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1987 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1987 |
Aminoglutethimide and ketoconazole: historical perspectives and future prospects.
Topics: Adrenal Gland Neoplasms; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Femal | 1988 |
Aminoglutethimide and ketoconazole: historical perspectives and future prospects.
Topics: Adrenal Gland Neoplasms; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Femal | 1988 |
Hormonal aspects of prostatic cancer: a review.
Topics: Adrenalectomy; Castration; Cyproterone; Diethylstilbestrol; Hormones; Humans; Hypophysectomy; Ketoco | 1985 |
Hormonal aspects of prostatic cancer: a review.
Topics: Adrenalectomy; Castration; Cyproterone; Diethylstilbestrol; Hormones; Humans; Hypophysectomy; Ketoco | 1985 |
The endocrine effects of ketoconazole.
Topics: Animals; Breast Neoplasms; Cushing Syndrome; Endocrine System Diseases; Female; Hirsutism; Humans; K | 1986 |
The endocrine effects of ketoconazole.
Topics: Animals; Breast Neoplasms; Cushing Syndrome; Endocrine System Diseases; Female; Hirsutism; Humans; K | 1986 |
[New hormonal treatments of metastatic prostatic cancer. Review of the literature].
Topics: Aminoglutethimide; Androgen Antagonists; Animals; Antineoplastic Agents; Combined Modality Therapy; | 1985 |
[New hormonal treatments of metastatic prostatic cancer. Review of the literature].
Topics: Aminoglutethimide; Androgen Antagonists; Animals; Antineoplastic Agents; Combined Modality Therapy; | 1985 |
36 trials available for ketoconazole and Prostatic Neoplasms
| Article | Year |
|---|---|
Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Granulocyte-Macr | 2013 |
Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Granulocyte-Macr | 2013 |
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Com | 2013 |
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Com | 2013 |
Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgen Antagonists; Androgen Receptor Antag | 2014 |
Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgen Antagonists; Androgen Receptor Antag | 2014 |
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Ag | 2008 |
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Ag | 2008 |
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Pro | 2008 |
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Pro | 2008 |
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgens; Azasteroids; Cholestenone 5 alpha-Reductase; Dutasteride; | 2009 |
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgens; Azasteroids; Cholestenone 5 alpha-Reductase; Dutasteride; | 2009 |
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic | 2010 |
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic | 2010 |
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic | 2010 |
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic | 2010 |
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic | 2010 |
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic | 2010 |
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic | 2010 |
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic | 2010 |
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Drug Interacti | 2010 |
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Drug Interacti | 2010 |
Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Agents, Hor | 2011 |
Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Agents, Hor | 2011 |
A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middl | 2011 |
A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middl | 2011 |
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin | 2003 |
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin | 2003 |
Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Human | 2003 |
Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Human | 2003 |
Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Anticoagulants; Antineoplastic Agents, Hormonal; | 2003 |
Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Anticoagulants; Antineoplastic Agents, Hormonal; | 2003 |
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2004 |
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2004 |
An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Humans; Ketoconazole; Male; Middle Aged; Prostatic Ne | 2004 |
An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Humans; Ketoconazole; Male; Middle Aged; Prostatic Ne | 2004 |
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2005 |
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2005 |
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
Topics: Aged; Alendronate; Bone Neoplasms; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middle Age | 2005 |
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
Topics: Aged; Alendronate; Bone Neoplasms; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middle Age | 2005 |
Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Ketoconazole; Male; | 2006 |
Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Ketoconazole; Male; | 2006 |
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
Topics: Adrenal Glands; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Drug Resistance, Neoplasm; | 2007 |
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
Topics: Adrenal Glands; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Drug Resistance, Neoplasm; | 2007 |
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Topics: Administration, Oral; Aged; Aged, 80 and over; Biopsy, Needle; Dose-Response Relationship, Drug; Dru | 2007 |
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Topics: Administration, Oral; Aged; Aged, 80 and over; Biopsy, Needle; Dose-Response Relationship, Drug; Dru | 2007 |
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Aged; Algorithms; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Confidence | 2007 |
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Aged; Algorithms; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Confidence | 2007 |
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Computational Biology; Cytochrome P-450 CYP3A | 2008 |
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Computational Biology; Cytochrome P-450 CYP3A | 2008 |
Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxor | 1994 |
Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxor | 1994 |
Acquired cutaneous adherence in patients with androgen-independent prostate cancer receiving ketoconazole and doxorubicin: medication-induced sticky skin.
Topics: Adhesiveness; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antig | 1995 |
Acquired cutaneous adherence in patients with androgen-independent prostate cancer receiving ketoconazole and doxorubicin: medication-induced sticky skin.
Topics: Adhesiveness; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antig | 1995 |
Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Glucocorticoids; Humans; Imidazoles; Ketoconazole; Ma | 1993 |
Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Glucocorticoids; Humans; Imidazoles; Ketoconazole; Ma | 1993 |
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Hy | 1997 |
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Hy | 1997 |
Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androgen Antagonists; Cohort Studies; Flutamide; H | 1997 |
Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androgen Antagonists; Cohort Studies; Flutamide; H | 1997 |
Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neopl | 1997 |
Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neopl | 1997 |
Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results.
Topics: Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2000 |
Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results.
Topics: Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2000 |
Hormone therapy of prostatic bone metastases.
Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbest | 1992 |
Hormone therapy of prostatic bone metastases.
Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbest | 1992 |
[Results of a clinical trial of ketoconazole in metastatic prostatic carcinoma].
Topics: Aged; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms | 1991 |
[Results of a clinical trial of ketoconazole in metastatic prostatic carcinoma].
Topics: Aged; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms | 1991 |
Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Humans; Ketoconazole; Male; Middle Aged; Nausea; | 1987 |
Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Humans; Ketoconazole; Male; Middle Aged; Nausea; | 1987 |
Effects of high-dose ketoconazole on patients who have androgen-independent prostatic cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Neoplasms; Clinical Trials as Topic; Drug Administr | 1989 |
Effects of high-dose ketoconazole on patients who have androgen-independent prostatic cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Neoplasms; Clinical Trials as Topic; Drug Administr | 1989 |
Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Clinical Trials as | 1989 |
Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Clinical Trials as | 1989 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1987 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1987 |
Effects of high-dose ketoconazole and dexamethasone on ACTH-stimulated adrenal steroidogenesis in orchiectomized prostatic cancer patients.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Aged; Androgens; Combined Modality Therapy; De | 1987 |
Effects of high-dose ketoconazole and dexamethasone on ACTH-stimulated adrenal steroidogenesis in orchiectomized prostatic cancer patients.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Aged; Androgens; Combined Modality Therapy; De | 1987 |
116 other studies available for ketoconazole and Prostatic Neoplasms
| Article | Year |
|---|---|
Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis.
Topics: Adamantane; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds; Drug Resistance; Enzyme Inhib | 1995 |
Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis.
Topics: Adamantane; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds; Drug Resistance; Enzyme Inhib | 1995 |
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.
Topics: Cytochrome P-450 Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Male; Prostatic Neoplas | 1995 |
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.
Topics: Cytochrome P-450 Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Male; Prostatic Neoplas | 1995 |
3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer.
Topics: Adamantane; Animals; Antineoplastic Agents; Enzyme Inhibitors; Esterases; Humans; Kinetics; Male; Mi | 1996 |
3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer.
Topics: Adamantane; Animals; Antineoplastic Agents; Enzyme Inhibitors; Esterases; Humans; Kinetics; Male; Mi | 1996 |
Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; | 1998 |
Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; | 1998 |
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cricetinae; Cytochrome P-450 Enzyme Inhibitors; Cy | 2004 |
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cricetinae; Cytochrome P-450 Enzyme Inhibitors; Cy | 2004 |
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; | 2005 |
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; | 2005 |
Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Topics: Androstenes; Androstenols; Biphenyl Compounds; Enzyme Inhibitors; Humans; Male; Models, Molecular; P | 2008 |
Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Topics: Androstenes; Androstenols; Biphenyl Compounds; Enzyme Inhibitors; Humans; Male; Models, Molecular; P | 2008 |
Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Topics: Antineoplastic Agents, Hormonal; Biphenyl Compounds; Enzyme Inhibitors; Humans; Inhibitory Concentra | 2010 |
Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Topics: Antineoplastic Agents, Hormonal; Biphenyl Compounds; Enzyme Inhibitors; Humans; Inhibitory Concentra | 2010 |
Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Topics: Androgen Antagonists; Animals; Biphenyl Compounds; Cell Line; Cricetinae; Cricetulus; Humans; Imidaz | 2010 |
Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Topics: Androgen Antagonists; Animals; Biphenyl Compounds; Cell Line; Cricetinae; Cricetulus; Humans; Imidaz | 2010 |
In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
Topics: 14-alpha Demethylase Inhibitors; 5-alpha Reductase Inhibitors; Animals; Bile; Drug Interactions; Fin | 2011 |
In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole.
Topics: 14-alpha Demethylase Inhibitors; 5-alpha Reductase Inhibitors; Animals; Bile; Drug Interactions; Fin | 2011 |
Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Cholestenone 5 alpha-Reductase; C | 2014 |
Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Cholestenone 5 alpha-Reductase; C | 2014 |
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Topics: Androgen Receptor Antagonists; Androstadienes; Benzimidazoles; Clinical Trials as Topic; Drug Discov | 2015 |
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Topics: Androgen Receptor Antagonists; Androstadienes; Benzimidazoles; Clinical Trials as Topic; Drug Discov | 2015 |
Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Topics: Androgens; Androstenes; Antineoplastic Agents, Hormonal; Catalytic Domain; Cytochrome P-450 CYP3A; E | 2021 |
Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Topics: Androgens; Androstenes; Antineoplastic Agents, Hormonal; Catalytic Domain; Cytochrome P-450 CYP3A; E | 2021 |
Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Clotrimazole; DNA, Neoplasm; Humans; Ketoconazole; Male; Prostatic Neop | 2013 |
Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Clotrimazole; DNA, Neoplasm; Humans; Ketoconazole; Male; Prostatic Neop | 2013 |
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Combined Modali | 2014 |
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Combined Modali | 2014 |
Commentary on "Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel." Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berge
Topics: Androstadienes; Antineoplastic Agents; Humans; Ketoconazole; Male; Orchiectomy; Prostatic Neoplasms; | 2016 |
Commentary on "Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel." Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berge
Topics: Androstadienes; Antineoplastic Agents; Humans; Ketoconazole; Male; Orchiectomy; Prostatic Neoplasms; | 2016 |
Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Gonadotropin-Releasing Hormone; Humans; Ketoc | 2015 |
Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Gonadotropin-Releasing Hormone; Humans; Ketoc | 2015 |
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Prost | 2009 |
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Prost | 2009 |
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Castration; Cell Line, Tumor; Cinnamates; Diseas | 2009 |
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
Topics: Androgen Antagonists; Androgens; Anilides; Animals; Castration; Cell Line, Tumor; Cinnamates; Diseas | 2009 |
Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; | 2009 |
Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; | 2009 |
Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bridged-Ring Compounds; Castration; Dis | 2010 |
Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bridged-Ring Compounds; Castration; Dis | 2010 |
CYP24A1 inhibition enhances the antitumor activity of calcitriol.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Calcitriol; Calcium; Caspase 3; Cell L | 2010 |
CYP24A1 inhibition enhances the antitumor activity of calcitriol.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Calcitriol; Calcium; Caspase 3; Cell L | 2010 |
Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Drug Interactions; Drug Resist | 2010 |
Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Drug Interactions; Drug Resist | 2010 |
Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Drug Interactions; Drug Therapy, Combination; Feno | 2011 |
Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Drug Interactions; Drug Therapy, Combination; Feno | 2011 |
Secondary hormonal manipulations in the treatment of castration refractory prostate cancer.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic | 2011 |
Secondary hormonal manipulations in the treatment of castration refractory prostate cancer.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic | 2011 |
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
Topics: Adrenal Glands; Aged; Aged, 80 and over; Androgens; Cohort Studies; Disease Progression; Dose-Respon | 2012 |
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
Topics: Adrenal Glands; Aged; Aged, 80 and over; Androgens; Cohort Studies; Disease Progression; Dose-Respon | 2012 |
Editorial comment.
Topics: Antineoplastic Agents; Docetaxel; Humans; Ketoconazole; Male; Prostatic Neoplasms; Taxoids | 2011 |
Editorial comment.
Topics: Antineoplastic Agents; Docetaxel; Humans; Ketoconazole; Male; Prostatic Neoplasms; Taxoids | 2011 |
Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Humans; Ketoconazole; Male; P | 2011 |
Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Humans; Ketoconazole; Male; P | 2011 |
Radiation port dermatophytosis: tinea corporis occurring at the site of irradiated skin.
Topics: Adenocarcinoma; Aged; Antifungal Agents; Humans; Ketoconazole; Male; Prostatic Neoplasms; Radioderma | 2012 |
Radiation port dermatophytosis: tinea corporis occurring at the site of irradiated skin.
Topics: Adenocarcinoma; Aged; Antifungal Agents; Humans; Ketoconazole; Male; Prostatic Neoplasms; Radioderma | 2012 |
[Efficacy of low dose ketoconazole therapy for Chinese patients with castration resistant prostate cancer].
Topics: Aged; Castration; Humans; Ketoconazole; Logistic Models; Male; Multivariate Analysis; Prostate-Speci | 2012 |
[Efficacy of low dose ketoconazole therapy for Chinese patients with castration resistant prostate cancer].
Topics: Aged; Castration; Humans; Ketoconazole; Logistic Models; Male; Multivariate Analysis; Prostate-Speci | 2012 |
The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?
Topics: Aged; Humans; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms | 2012 |
The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?
Topics: Aged; Humans; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms | 2012 |
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Gonadotropin-Releasing Hormone | 2012 |
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Gonadotropin-Releasing Hormone | 2012 |
Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Biomarkers, Tumor; Disease | 2002 |
Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Biomarkers, Tumor; Disease | 2002 |
Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cell Division; Cytochrome P-450 Enzyme I | 2002 |
Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cell Division; Cytochrome P-450 Enzyme I | 2002 |
Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer.
Topics: Aged; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase | 2003 |
Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer.
Topics: Aged; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase | 2003 |
National Cancer Institute intramural approach to advanced prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomedical Research; Cancer Vaccines; Clinical Trials as Topi | 2002 |
National Cancer Institute intramural approach to advanced prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomedical Research; Cancer Vaccines; Clinical Trials as Topi | 2002 |
Gamma-tocotrienol metabolism and antiproliferative effect in prostate cancer cells.
Topics: Cell Division; Chromans; Humans; Ketoconazole; Male; Prostatic Neoplasms; Tumor Cells, Cultured; Vit | 2004 |
Gamma-tocotrienol metabolism and antiproliferative effect in prostate cancer cells.
Topics: Cell Division; Chromans; Humans; Ketoconazole; Male; Prostatic Neoplasms; Tumor Cells, Cultured; Vit | 2004 |
Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; | 2005 |
Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; | 2005 |
Prostate cancer metastasis to supraclavicular lymph node.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Prot | 2004 |
Prostate cancer metastasis to supraclavicular lymph node.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Prot | 2004 |
Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
Topics: Androgens; Animals; Cell Cycle Proteins; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; | 2006 |
Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
Topics: Androgens; Animals; Cell Cycle Proteins; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; | 2006 |
An evaluation of high-doses ketoconazole with hydrocortisone substitution in hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Dis | 2005 |
An evaluation of high-doses ketoconazole with hydrocortisone substitution in hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Dis | 2005 |
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progress | 2006 |
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progress | 2006 |
A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gene Expression; Gene Ex | 2006 |
A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gene Expression; Gene Ex | 2006 |
Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Drug Interactions; | 2007 |
Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Drug Interactions; | 2007 |
Non-interventional management of obstructive acute renal-failure in hormone-naïve prostate cancer.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Aged; Fatal Outcome; Humans; Ketoconazole; Male; Middl | 2007 |
Non-interventional management of obstructive acute renal-failure in hormone-naïve prostate cancer.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Aged; Fatal Outcome; Humans; Ketoconazole; Male; Middl | 2007 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bon | 2007 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bon | 2007 |
Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Humans; Ketoconazole; Male | 2007 |
Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Humans; Ketoconazole; Male | 2007 |
Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic Agents; Doce | 2008 |
Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic Agents; Doce | 2008 |
Treatment of advanced carcinoma of the prostate.
Topics: Castration; Combined Modality Therapy; Diethylstilbestrol; Humans; Ketoconazole; Male; Prostatic Neo | 1984 |
Treatment of advanced carcinoma of the prostate.
Topics: Castration; Combined Modality Therapy; Diethylstilbestrol; Humans; Ketoconazole; Male; Prostatic Neo | 1984 |
The effects of ketoconazole on testosterone production and normal and malignant androgen dependent tissues of the adult rat.
Topics: Adenocarcinoma; Animals; Castration; Depression, Chemical; Gonadotropin-Releasing Hormone; Half-Life | 1984 |
The effects of ketoconazole on testosterone production and normal and malignant androgen dependent tissues of the adult rat.
Topics: Adenocarcinoma; Animals; Castration; Depression, Chemical; Gonadotropin-Releasing Hormone; Half-Life | 1984 |
[Hormonal manipulation of disseminated prostatic cancer].
Topics: Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Prostatic Neoplasms; Testosterone | 1984 |
[Hormonal manipulation of disseminated prostatic cancer].
Topics: Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Prostatic Neoplasms; Testosterone | 1984 |
Endocrine therapy: non-estrogenic pharmacological manipulation.
Topics: Animals; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Prostatic Neoplasms; Testostero | 1983 |
Endocrine therapy: non-estrogenic pharmacological manipulation.
Topics: Animals; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Prostatic Neoplasms; Testostero | 1983 |
Ketoconazole therapy for advanced prostate cancer.
Topics: Acid Phosphatase; Aged; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1984 |
Ketoconazole therapy for advanced prostate cancer.
Topics: Acid Phosphatase; Aged; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1984 |
Ketoconazole for prostate cancer.
Topics: Castration; Combined Modality Therapy; Humans; Ketoconazole; Male; Prostatic Neoplasms; Testosterone | 1984 |
Ketoconazole for prostate cancer.
Topics: Castration; Combined Modality Therapy; Humans; Ketoconazole; Male; Prostatic Neoplasms; Testosterone | 1984 |
Ketoconazole: a novel and rapid treatment for advanced prostatic cancer.
Topics: Aged; Carcinoma; Humans; Imidazoles; Ketoconazole; Male; Piperazines; Prostatic Neoplasms | 1983 |
Ketoconazole: a novel and rapid treatment for advanced prostatic cancer.
Topics: Aged; Carcinoma; Humans; Imidazoles; Ketoconazole; Male; Piperazines; Prostatic Neoplasms | 1983 |
Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.
Topics: Adenocarcinoma; Aged; Drug Resistance; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Go | 1983 |
Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.
Topics: Adenocarcinoma; Aged; Drug Resistance; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Go | 1983 |
Ketoconazole therapy in advanced prostatic cancer.
Topics: Acid Phosphatase; Aged; Androstenedione; Dehydroepiandrosterone; Follow-Up Studies; Humans; Ketocona | 1984 |
Ketoconazole therapy in advanced prostatic cancer.
Topics: Acid Phosphatase; Aged; Androstenedione; Dehydroepiandrosterone; Follow-Up Studies; Humans; Ketocona | 1984 |
Pyridyl substituted benzocycloalkenes: new inhibitors of 17 alpha-hydroxylase/17,20-lyase (P450 17 alpha).
Topics: Aldehyde-Lyases; Animals; Antineoplastic Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-45 | 1994 |
Pyridyl substituted benzocycloalkenes: new inhibitors of 17 alpha-hydroxylase/17,20-lyase (P450 17 alpha).
Topics: Aldehyde-Lyases; Animals; Antineoplastic Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-45 | 1994 |
Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Doxorubicin; Drug Resista | 1994 |
Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Doxorubicin; Drug Resista | 1994 |
Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 1994 |
Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 1994 |
In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Drug Synergism; Ga | 1997 |
In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Drug Synergism; Ga | 1997 |
Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Topics: Androgens; Animals; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Enzyme Inhibitors; Finaster | 1998 |
Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Topics: Androgens; Animals; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Enzyme Inhibitors; Finaster | 1998 |
Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma.
Topics: Aged; Aminoglutethimide; Epithelial Cells; Humans; Immunohistochemistry; Ketoconazole; Male; Middle | 1996 |
Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma.
Topics: Aged; Aminoglutethimide; Epithelial Cells; Humans; Immunohistochemistry; Ketoconazole; Male; Middle | 1996 |
Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Humans; Ketoconazole; Male; Microtubules; P | 2000 |
Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Humans; Ketoconazole; Male; Microtubules; P | 2000 |
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgen Receptor Antagonists; Androstadienes; A | 2000 |
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgen Receptor Antagonists; Androstadienes; A | 2000 |
Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma.
Topics: ACTH Syndrome, Ectopic; Adenocarcinoma; Adrenocorticotropic Hormone; Aged; Alkalosis; Comorbidity; C | 2001 |
Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma.
Topics: ACTH Syndrome, Ectopic; Adenocarcinoma; Adrenocorticotropic Hormone; Aged; Alkalosis; Comorbidity; C | 2001 |
Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Antigens, Neoplasm; Biomarkers, Tumor; Drug Therapy, Combination; Humans; Ketoconazo | 1990 |
Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Antigens, Neoplasm; Biomarkers, Tumor; Drug Therapy, Combination; Humans; Ketoconazo | 1990 |
Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Humans; Ketoconazole; Male; Prednisone; Prostate-Specific Ant | 1991 |
Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Humans; Ketoconazole; Male; Prednisone; Prostate-Specific Ant | 1991 |
[Ketoconazole inhibits the growth of prostatic squamous carcinoma, at which time testicular androgen enhanced in tumor bearing rat].
Topics: Adrenal Glands; Androgens; Animals; Carcinoma, Squamous Cell; Ketoconazole; Male; Orchiectomy; Prost | 1991 |
[Ketoconazole inhibits the growth of prostatic squamous carcinoma, at which time testicular androgen enhanced in tumor bearing rat].
Topics: Adrenal Glands; Androgens; Animals; Carcinoma, Squamous Cell; Ketoconazole; Male; Orchiectomy; Prost | 1991 |
Ketoconazole for prostate cancer.
Topics: Adenocarcinoma; Humans; Ketoconazole; Male; Prostatic Neoplasms | 1990 |
Ketoconazole for prostate cancer.
Topics: Adenocarcinoma; Humans; Ketoconazole; Male; Prostatic Neoplasms | 1990 |
Indications for use of ketoconazole in management of metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Contraindications; Estrogens; Humans; Ketoconazol | 1990 |
Indications for use of ketoconazole in management of metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Contraindications; Estrogens; Humans; Ketoconazol | 1990 |
[Hormone treatment of prostate carcinoma: past achievements and current perspectives].
Topics: Adrenalectomy; Aged; Androgen Antagonists; Estrogen Antagonists; Estrogens; Hormones; Humans; Ketoco | 1986 |
[Hormone treatment of prostate carcinoma: past achievements and current perspectives].
Topics: Adrenalectomy; Aged; Androgen Antagonists; Estrogen Antagonists; Estrogens; Hormones; Humans; Ketoco | 1986 |
Management of metastatic prostatic carcinoma.
Topics: Adrenalectomy; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Gona | 1986 |
Management of metastatic prostatic carcinoma.
Topics: Adrenalectomy; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Diethylstilbestrol; Gona | 1986 |
High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Androstenedione; Antigens, Neoplasm; Biomarkers, Tumor; D | 1989 |
High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Androstenedione; Antigens, Neoplasm; Biomarkers, Tumor; D | 1989 |
The effects of a new imidazole derivative in advanced prostatic cancer. A preliminary report.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Humans; Imidazoles; Ketoconazole; Ma | 1989 |
The effects of a new imidazole derivative in advanced prostatic cancer. A preliminary report.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Humans; Imidazoles; Ketoconazole; Ma | 1989 |
Synergistic effect of ketoconazole and antineoplastic agents on hormone-independent prostatic cancer cells.
Topics: Antineoplastic Agents; Cell Survival; Clone Cells; Drug Synergism; Humans; Ketoconazole; Male; Prost | 1989 |
Synergistic effect of ketoconazole and antineoplastic agents on hormone-independent prostatic cancer cells.
Topics: Antineoplastic Agents; Cell Survival; Clone Cells; Drug Synergism; Humans; Ketoconazole; Male; Prost | 1989 |
Emergency treatment with ketoconazole in disseminated intravascular coagulation due to metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Disseminated Intravascular Coagulation; Emergencies; Humans; K | 1989 |
Emergency treatment with ketoconazole in disseminated intravascular coagulation due to metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Disseminated Intravascular Coagulation; Emergencies; Humans; K | 1989 |
Comparative effects of ketoconazole on rat, dog and human testicular steroidogenesis.
Topics: Aged; Androgens; Animals; Cells, Cultured; Chorionic Gonadotropin; Dogs; Humans; Ketoconazole; Kinet | 1989 |
Comparative effects of ketoconazole on rat, dog and human testicular steroidogenesis.
Topics: Aged; Androgens; Animals; Cells, Cultured; Chorionic Gonadotropin; Dogs; Humans; Ketoconazole; Kinet | 1989 |
Neurologic complications of ketoconazole therapy for advanced prostatic cancer.
Topics: Adenocarcinoma; Aged; Brain Diseases; Humans; Ketoconazole; Male; Prostatic Neoplasms; Radiography | 1989 |
Neurologic complications of ketoconazole therapy for advanced prostatic cancer.
Topics: Adenocarcinoma; Aged; Brain Diseases; Humans; Ketoconazole; Male; Prostatic Neoplasms; Radiography | 1989 |
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Topics: Adrenocorticotropic Hormone; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Pr | 1988 |
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Topics: Adrenocorticotropic Hormone; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Pr | 1988 |
Adrenal hypofunction in patients taking ketoconazole.
Topics: Adrenal Insufficiency; Humans; Hydrocortisone; Ketoconazole; Male; Prostatic Neoplasms | 1985 |
Adrenal hypofunction in patients taking ketoconazole.
Topics: Adrenal Insufficiency; Humans; Hydrocortisone; Ketoconazole; Male; Prostatic Neoplasms | 1985 |
Hypertension during high-dose ketoconazole treatment: a probable mineralocorticosteroid effect.
Topics: Blood Pressure; Humans; Hypertension; Ketoconazole; Male; Mineralocorticoids; Prostatic Neoplasms | 1987 |
Hypertension during high-dose ketoconazole treatment: a probable mineralocorticosteroid effect.
Topics: Blood Pressure; Humans; Hypertension; Ketoconazole; Male; Mineralocorticoids; Prostatic Neoplasms | 1987 |
Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells.
Topics: Carcinoma; Cell Line; Colony-Forming Units Assay; Humans; Ketoconazole; Male; Prostatic Neoplasms; T | 1989 |
Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells.
Topics: Carcinoma; Cell Line; Colony-Forming Units Assay; Humans; Ketoconazole; Male; Prostatic Neoplasms; T | 1989 |
High-dose ketoconazole therapy in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androstenedione; Combined Modality Therapy; Dehydroepiandrosterone; Dexamethas | 1986 |
High-dose ketoconazole therapy in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androstenedione; Combined Modality Therapy; Dehydroepiandrosterone; Dexamethas | 1986 |
Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Cortex Hormones; Aged; Androgens; Androstenedione; Corticoster | 1986 |
Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Cortex Hormones; Aged; Androgens; Androstenedione; Corticoster | 1986 |
Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Asthenia; Drug Administration Schedule; Drug Eruptions; Fea | 1987 |
Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Asthenia; Drug Administration Schedule; Drug Eruptions; Fea | 1987 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
Steroid synthesis inhibition by ketoconazole: sites of action.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aldehyde-Lyases; Androgens; Androstenedione; Chorionic Gonadotro | 1988 |
[Drug therapy of metastasizing prostate carcinoma with special reference to the bioavailability of fosfestrol after oral administration].
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents; Biological Availability; Bi | 1988 |
[Drug therapy of metastasizing prostate carcinoma with special reference to the bioavailability of fosfestrol after oral administration].
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents; Biological Availability; Bi | 1988 |
High-dose ketoconazole treatment in advanced prostatic cancer.
Topics: Aged; Androgens; Carrier Proteins; Humans; Ketoconazole; Male; Middle Aged; Progesterone; Prostatic | 1988 |
High-dose ketoconazole treatment in advanced prostatic cancer.
Topics: Aged; Androgens; Carrier Proteins; Humans; Ketoconazole; Male; Middle Aged; Progesterone; Prostatic | 1988 |
Ketoconazole in initial management and treatment of metastatic prostate cancer to spine.
Topics: Humans; Ketoconazole; Male; Prostatic Neoplasms; Spinal Neoplasms | 1988 |
Ketoconazole in initial management and treatment of metastatic prostate cancer to spine.
Topics: Humans; Ketoconazole; Male; Prostatic Neoplasms; Spinal Neoplasms | 1988 |
Current trends in the endocrine use of ketoconazole.
Topics: Chemical Phenomena; Chemistry; Cushing Syndrome; Endocrine System Diseases; Female; Hirsutism; Human | 1988 |
Current trends in the endocrine use of ketoconazole.
Topics: Chemical Phenomena; Chemistry; Cushing Syndrome; Endocrine System Diseases; Female; Hirsutism; Human | 1988 |
Effects of high-dose ketoconazole in patients with androgen-independent prostatic cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Humans; Ketoconazole; Male; Middle | 1988 |
Effects of high-dose ketoconazole in patients with androgen-independent prostatic cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Humans; Ketoconazole; Male; Middle | 1988 |
Ketoconazole therapy for hormonally refractive metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Bone Neoplasms; Carcinoma; Combined Modality Therapy; Diethylsti | 1988 |
Ketoconazole therapy for hormonally refractive metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Bone Neoplasms; Carcinoma; Combined Modality Therapy; Diethylsti | 1988 |
Cholesterol metabolism during ketoconazole treatment in man.
Topics: Aged; Bile; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Humans; Ketoconazole; Lipi | 1988 |
Cholesterol metabolism during ketoconazole treatment in man.
Topics: Aged; Bile; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Humans; Ketoconazole; Lipi | 1988 |
[High dosage ketoconazole therapy in the treatment of advanced prostatic cancer].
Topics: Aged; Bone Neoplasms; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Ketoconazole; Mal | 1988 |
[High dosage ketoconazole therapy in the treatment of advanced prostatic cancer].
Topics: Aged; Bone Neoplasms; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Ketoconazole; Mal | 1988 |
High-dose ketoconazole to untreated stage D prostate cancer.
Topics: Acid Phosphatase; Adult; Aged; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Prostatic Ne | 1988 |
High-dose ketoconazole to untreated stage D prostate cancer.
Topics: Acid Phosphatase; Adult; Aged; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Prostatic Ne | 1988 |
Ketoconazole as primary treatment of prostatic cancer.
Topics: Adrenal Cortex Hormones; Aged; Humans; Ketoconazole; Liver; Male; Middle Aged; Prostatic Neoplasms; | 1988 |
Ketoconazole as primary treatment of prostatic cancer.
Topics: Adrenal Cortex Hormones; Aged; Humans; Ketoconazole; Liver; Male; Middle Aged; Prostatic Neoplasms; | 1988 |
Ketoconazole high dose in the hormonal treatment of advanced carcinoma of the prostate. A pilot study.
Topics: Adenocarcinoma; Aged; Androgens; Hormones; Humans; Ketoconazole; Male; Pilot Projects; Prostatic Neo | 1987 |
Ketoconazole high dose in the hormonal treatment of advanced carcinoma of the prostate. A pilot study.
Topics: Adenocarcinoma; Aged; Androgens; Hormones; Humans; Ketoconazole; Male; Pilot Projects; Prostatic Neo | 1987 |
The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer.
Topics: Adenocarcinoma; Aged; Disseminated Intravascular Coagulation; Emergencies; Humans; Ketoconazole; Mal | 1987 |
The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer.
Topics: Adenocarcinoma; Aged; Disseminated Intravascular Coagulation; Emergencies; Humans; Ketoconazole; Mal | 1987 |
Ketoconazole therapy in advanced prostatic cancer.
Topics: Humans; Ketoconazole; Male; Prostatic Neoplasms | 1987 |
Ketoconazole therapy in advanced prostatic cancer.
Topics: Humans; Ketoconazole; Male; Prostatic Neoplasms | 1987 |
Disseminated intravascular coagulation in prostatic carcinoma reversed by ketoconazole.
Topics: Aged; Aged, 80 and over; Disseminated Intravascular Coagulation; Humans; Ketoconazole; Male; Prostat | 1987 |
Disseminated intravascular coagulation in prostatic carcinoma reversed by ketoconazole.
Topics: Aged; Aged, 80 and over; Disseminated Intravascular Coagulation; Humans; Ketoconazole; Male; Prostat | 1987 |
The endocrine effect of ketoconazole high doses (KHD).
Topics: Androgens; Glucocorticoids; Humans; Ketoconazole; Male; Mineralocorticoids; Prostatic Neoplasms; Tes | 1987 |
The endocrine effect of ketoconazole high doses (KHD).
Topics: Androgens; Glucocorticoids; Humans; Ketoconazole; Male; Mineralocorticoids; Prostatic Neoplasms; Tes | 1987 |
Side effects of ketoconazole therapy in advanced cancer of the prostate. A case report.
Topics: Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasms | 1987 |
Side effects of ketoconazole therapy in advanced cancer of the prostate. A case report.
Topics: Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasms | 1987 |
Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer.
Topics: Estrogens; Humans; Hydrocortisone; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Prostatic N | 1987 |
Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer.
Topics: Estrogens; Humans; Hydrocortisone; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Prostatic N | 1987 |
Inhibition of cholesterol synthesis by ketoconazole.
Topics: Aged; Carcinoma; Cholesterol; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasms | 1986 |
Inhibition of cholesterol synthesis by ketoconazole.
Topics: Aged; Carcinoma; Cholesterol; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasms | 1986 |
Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole.
Topics: Administration, Oral; Aged; Dexamethasone; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neopla | 1986 |
Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole.
Topics: Administration, Oral; Aged; Dexamethasone; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neopla | 1986 |
[Cancer of the prostate: new hormone therapies].
Topics: Androgen Antagonists; Cyproterone; Flutamide; Humans; Ketoconazole; Male; Medroxyprogesterone; Meges | 1986 |
[Cancer of the prostate: new hormone therapies].
Topics: Androgen Antagonists; Cyproterone; Flutamide; Humans; Ketoconazole; Male; Medroxyprogesterone; Meges | 1986 |
[Ketoconazole--new possibilities of treatment in advanced stages of prostatic carcinoma].
Topics: Androgens; Humans; Ketoconazole; Male; Prostatic Neoplasms | 1986 |
[Ketoconazole--new possibilities of treatment in advanced stages of prostatic carcinoma].
Topics: Androgens; Humans; Ketoconazole; Male; Prostatic Neoplasms | 1986 |
[Ketoconazole in the treatment of advanced cancer of the prostate: experience with 14 patients].
Topics: Acid Phosphatase; Aged; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neop | 1985 |
[Ketoconazole in the treatment of advanced cancer of the prostate: experience with 14 patients].
Topics: Acid Phosphatase; Aged; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neop | 1985 |
Antifungal agent for prostatic carcinoma.
Topics: Humans; Ketoconazole; Male; Prostatic Neoplasms | 1985 |
Antifungal agent for prostatic carcinoma.
Topics: Humans; Ketoconazole; Male; Prostatic Neoplasms | 1985 |
The effects of cyclophosphamide, ketoconazole, aclacinomycin-A, methotrexate, and scheduled methotrexate-5-fluorouracil combination chemotherapy on the transplantable R-3327 prostatic adenocarcinoma in the F1 hybrid male rat.
Topics: Aclarubicin; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1985 |
The effects of cyclophosphamide, ketoconazole, aclacinomycin-A, methotrexate, and scheduled methotrexate-5-fluorouracil combination chemotherapy on the transplantable R-3327 prostatic adenocarcinoma in the F1 hybrid male rat.
Topics: Aclarubicin; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1985 |
Endocrine effects of high-dose ketoconazole therapy in advanced prostatic cancer.
Topics: 17-Ketosteroids; Dose-Response Relationship, Drug; Estradiol; Follicle Stimulating Hormone; Humans; | 1985 |
Endocrine effects of high-dose ketoconazole therapy in advanced prostatic cancer.
Topics: 17-Ketosteroids; Dose-Response Relationship, Drug; Estradiol; Follicle Stimulating Hormone; Humans; | 1985 |
Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer.
Topics: Acid Phosphatase; Aged; Androstenedione; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasm | 1986 |
Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer.
Topics: Acid Phosphatase; Aged; Androstenedione; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasm | 1986 |
High-dose ketoconazole therapy in prostatic cancer. A pilot study.
Topics: Administration, Oral; Humans; Ketoconazole; Male; Pilot Projects; Prostatic Neoplasms | 1985 |
High-dose ketoconazole therapy in prostatic cancer. A pilot study.
Topics: Administration, Oral; Humans; Ketoconazole; Male; Pilot Projects; Prostatic Neoplasms | 1985 |
Clinical applications of ketoconazole in prostatic cancer.
Topics: Androstenedione; Humans; Ketoconazole; Male; Prostatic Neoplasms; Testosterone | 1985 |
Clinical applications of ketoconazole in prostatic cancer.
Topics: Androstenedione; Humans; Ketoconazole; Male; Prostatic Neoplasms; Testosterone | 1985 |
Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia.
Topics: Estradiol; Gynecomastia; Humans; Ketoconazole; Kinetics; Male; Prostatic Neoplasms; Sex Hormone-Bind | 1985 |
Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia.
Topics: Estradiol; Gynecomastia; Humans; Ketoconazole; Kinetics; Male; Prostatic Neoplasms; Sex Hormone-Bind | 1985 |